» Articles » PMID: 1101818

Nalidixic Acid: an Antibacterial Paradox

Overview
Specialty Pharmacology
Date 1975 Sep 1
PMID 1101818
Citations 65
Authors
Affiliations
Soon will be listed here.
Abstract

Nalidixic acid was found to be most bactericidal against various species of gram-negative bacteria at 50 to 200 mug/ml. With all species tested, increases in the concentration of nalidixic acid above this range reduced, rather than increased, its bactericidal effect so that, at levels in the region of 400 mug/ml, the drug was relatively bacteriostatic. Therefore, the mode of action of nalidixic acid at various concentrations was investigated. It was found that at the most bactericidal concentration deoxyribonucleic acid synthesis, but no ribonucleic acid (RNA) or protein synthesis, was inhibited. However at higher concentrations, where the drug is least bactericidal, both RNA and protein synthesis were found to be inhibited. Results are presented which suggest that the protein synthesis inhibition is a secondary manifestation of the ability of the drug to inhibit RNA synthesis, and that of RNA synthesis is most likely the second target site for the action of the drug when bacteria are exposed to it in high concentrations. The clinical implications of these findings are discussed.

Citing Articles

Genomic and metabolic characterization of isolated from domestic and wild animals.

Magossi G, Gzyl K, Holman D, Nagaraja T, Amachawadi R, Amat S Appl Environ Microbiol. 2025; 91(1):e0172524.

PMID: 39745423 PMC: 11784230. DOI: 10.1128/aem.01725-24.


Unusual and Unconsidered Mechanisms of Bacterial Resilience and Resistance to Quinolones.

Ruiz J Life (Basel). 2024; 14(3).

PMID: 38541707 PMC: 10971285. DOI: 10.3390/life14030383.


Metabolic dormancy in treated with different antibiotics.

Rockey D, Wang X, Debrine A, Grieshaber N, Grieshaber S Infect Immun. 2024; 92(2):e0033923.

PMID: 38214508 PMC: 10863404. DOI: 10.1128/iai.00339-23.


Prophage Gifsy-1 Induction in Salmonella enterica Serovar Typhimurium Reduces Persister Cell Formation after Ciprofloxacin Exposure.

Braetz S, Schwerk P, Figueroa-Bossi N, Tedin K, Fulde M Microbiol Spectr. 2023; 11(4):e0187423.

PMID: 37306609 PMC: 10433948. DOI: 10.1128/spectrum.01874-23.


Metabolic profiling of UHPLC-HRMS-MS with computer-assisted structure elucidation and its antimicrobial activity.

Hu H, Tekin V, Hu B, Yaghoobi M, Khan A, Ghosh A Front Plant Sci. 2023; 14:1138913.

PMID: 37229132 PMC: 10205022. DOI: 10.3389/fpls.2023.1138913.


References
1.
Winshell E, Rosenkranz H . Nalidixic Acid and the Metabolism of Escherichia coli. J Bacteriol. 1970; 104(3):1168-75. PMC: 248274. DOI: 10.1128/jb.104.3.1168-1175.1970. View

2.
Goss W, Deitz W, Cook T . MECHANISM OF ACTION OF NALIDIXIC ACID ON ESCHERICHIA COLI.II. INHIBITION OF DEOXYRIBONUCLEIC ACID SYNTHESIS. J Bacteriol. 1965; 89:1068-74. PMC: 277597. DOI: 10.1128/jb.89.4.1068-1074.1965. View

3.
Bourguignon G, Levitt M, Sternglanz R . Studies on the mechanism of action of nalidixic acid. Antimicrob Agents Chemother. 1973; 4(4):479-86. PMC: 444580. DOI: 10.1128/AAC.4.4.479. View

4.
Datta N, Hedges R . Trimethoprim resistance conferred by W plasmids in Enterobacteriaceae. J Gen Microbiol. 1972; 72(2):349-55. DOI: 10.1099/00221287-72-2-349. View

5.
Schubach W, Whitmer J, Davern C . Genetic control of DNA initiation in Escherichia coli. J Mol Biol. 1973; 74(2):205-21. DOI: 10.1016/0022-2836(73)90107-1. View